What is the recommended dose of avatrombopag tablets/sucoxin at one time?

The recommended dosage of Avatrombopag/Suxin (Avatrombopag) is different when treating different types of thrombocytopenia. The specific dosage needs to be adjusted individually according to the patient's condition and changes in platelet count. For patients with primary immune thrombocytopenia (ITP), the recommended starting dose is 20 mg once daily. This dose is determined based on clinical trial data to ensure maximum efficacy while avoiding side effects caused by overdose. Doctors usually adjust the dosage based on the patient's clinical response and tolerance during treatment. The maximum recommended dose is 40 mg once daily, but this dose is generally reserved for patients with low platelet counts who do not respond effectively to the starting dose.

Avatropopag is administered differently in patients with thrombocytopenia associated with chronic liver disease (CLD). Especially when a patient is scheduled to undergo an invasive test or surgery, treatment usually begins 10 to 13 days before surgery. For patients with platelet counts below 40×10⁹/L, the recommended dose is 60 mg once a day for 5 days; for patients with platelet counts between 40×10⁹/L and 50×10⁹/L, the recommended dose is 40 mg once a day for 5 days.

During the treatment process, patients need to undergo regular check-ups under the guidance of a doctor to ensure that the platelet count can be maintained at an ideal level and the dosage can be adjusted in a timely manner. Under normal circumstances, the dose of avatrombopag will be flexibly adjusted according to the patient's platelet response to ensure therapeutic efficacy and safety.

In short, the recommended dose of avatrombopag varies according to the patient's condition. When using it, the platelet count needs to be closely monitored and the dose adjusted to achieve the best therapeutic effect. With reasonable medication management, avatrombopag can significantly improve platelet counts and effectively reduce the risk of bleeding. It is especially suitable for patients who need to increase platelet counts to improve clinical symptoms.

Reference materials:https://go.drugbank.com/drugs/DB11995